Stock Alert: Epizyme Inc (NASDAQ:EPZM), Eli Lilly and Co (NYSE:LLY), Oncomed Pharmaceuticals Inc (NASDAQ:OMED), OTSUKA HOLDINGS CO. (OTCMKTS: OTSKY)

On last trading day company shares ended up $30.01. Analysts mean target price for the company is $43.33. Epizyme Inc (NASDAQ:EPZM) distance from 50-day simple moving average (SMA50) is 20.24%.

On 17 JUNE Eli Lilly and Co (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals, Inc. announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the U.S. Food and Drug Administration (FDA). Eli Lilly and Co (NYSE:LLY) shares fell -0.24% in last trading session and ended the day on $62.46. LLY Gross Margin is 77.60% and its return on assets is 11.30%. Eli Lilly and Co (NYSE:LLY) quarterly performance is 7.43%.

On 7 JULY Oncomed Pharmaceuticals Inc (NASDAQ:OMED) reported ($0.47) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.13) by $0.34. Analysts expect that Oncomed Pharmaceuticals will post $-0.76 EPS for the current fiscal year. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) shares moved down -5.12% in last trading session and was closed at $20.95, while trading in range of $20.52 – $22.91. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) year to date (YTD) performance is -29.03%.

On 11 JUNE OTSUKA HOLDINGS CO. (OTCMKTS:OTSKY) announced that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder. OTSUKA HOLDINGS CO. (OTCMKTS: OTSKY) ended the last trading day at $15.77.